Skip to main content




Turkey says China's Sinovac COVID-19 vaccine 91.25% effective in late trials

Turkey says China's Sinovac COVID-19 vaccine 91.25% effective in late trials

FILE PHOTO: A display shows packages of vaccine candidate for SARS-CoV-2 by Sinovac Biotech during a government-organised media tour in Beijing, China, on Sep 24, 2020. (Photo: Reuters/Thomas Peter)

ANKARA: A COVID-19 vaccine developed by China's Sinovac Biotech is 91.25 per cent effective, according to interim data from a late-stage trial in Turkey, a potentially much better result than reported from a separate trial of the vaccine in Brazil.

Turkish researchers said on Thursday (Dec 24) no major side-effects were seen during their trial, apart from one person who had an allergic reaction. Common adverse effects caused by the vaccine were fever, mild pain and slight fatigue, they said.

Researchers in Brazil, which is also running a final Phase 3 trial of the vaccine, said on Wednesday the shot was more than 50 per cent effective, but withheld full results at the company's request, raising questions about transparency.

READ: Brazil institute says CoronaVac efficacy above 50%, but delays full results

The Turkish trials began on Sep 14 and have included more than 7,000 volunteers, the researchers said, adding the results announced on Thursday were based on data from 1,322 people.

Sinovac is the first Chinese vaccine maker to release details from late-stage clinical trials, following positive results from rival products developed by Pfizer, Moderna and AstraZeneca last month.

The Turkish researchers, speaking alongside Health Minister Fahrettin Koca, said 26 of the 29 people who were infected during the trial were given placebos, adding the trial would continue until 40 people become infected.

"We are now certain that the vaccine is effective and safe (to use) on Turkish people," Koca said, adding Ankara would use the data for licensing the vaccine.

He also said that researchers initially planned to announce the results after 40 people were infected, but that the findings showed the volunteers had minimal adverse effects after the shot and that it was therefore deemed safe.

"Despite it being risky, we saw a very light picture where three people's PCR COVID-19 test were positive, with no fever or respiratory problems ... We can easily say that despite it being risky, those three people went through it very lightly," he said.

READ: Turkey's daily COVID-19 deaths at record 246


Turkey had agreed to buy 50 million doses of Sinovac's shot and receive delivery by Dec 11 but the shipment was delayed.

Koca said three million doses would arrive on Monday, adding that Turkey would vaccinate some nine million people in the first group, starting with health workers.

CoronaVac has been given to tens of thousands of people under an emergency use programme China launched in July targeting specific groups of high-infection risks.

CoronaVac is based on traditional vaccine technology that uses inactivated coronavirus that cannot replicate in human cells to trigger an immune response.

Vaccines developed by Pfizer-BioNTech and Moderna use a new technology called synthetic messenger RNA (mRNA) to activate the immune system against the virus and require far colder storage.

READ: Pfizer-BioNTech, Moderna and Sinovac: A look at three key COVID-19 vaccines

Pfizer's treatment is the first fully tested COVID-19 shot to be administered, with rollout already under way in Britain and the United States.

Koca said Turkey would sign a deal with Pfizer-BioNTech for 4.5 million doses of their vaccine to be delivered by the end of March, with an option to buy a further 30 million doses later.

On Thursday, Turkey's death toll from the coronavirus rose by 254 to 19,115, according to Health Ministry data, while the total number of COVID-19 infections rose by 18,102.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak:

Source: Reuters/mi


Also worth reading